Hemoglobin Molecule
1
The Globin Chain Cluster on Chromosomes 16 and 11
2
Synthesis of Individual Globin Chains in Prenatal and Postnatal Life
3
The Expression of Human Globin Gene
4
Synthesis of Hemoglobin
5
Hemoglobin Abnormalities •Reduced rate of synthesis of normal α - or β - globin chains: thalassemia •Synthesis of an abnormal hemoglobin: hemoglobinopathy
6
The Clinical Syndromes Caused by Hemoglobin Abnormalities
Syndrome Thalassemia Hemoglobinopathy
Abnormality Reduced globin chain synthesis (α - or β -thalassemia) Abnormal Hb
Hemolysis
Crystalline hemoglobins (Hb S,C, D, E) or unstable hemoglobins
Familial polycythemia
Altered oxygen affinity
Methemoglobinemia
Failure of reduction (HbM)
7
The Geographical Distribution of Thalassemias and Hemoglobin Abnormalities
8
Thalassemias
9
Pathophysiology of β -Thalassemia (1)
10
Pathophysiology of β -Thalassemia (2)
11
12
Examples of Mutations Which Produce β -Thalassemia
•FS frame shifts •NS non-sense •SPL splicing 13
14
15
Thalassemia Major: Appearance and Skull X-ray
16
17
Peripheral Blood of Thalassemia Major
18
β -Thalassemia Major: Biopsy of Liver Before and After Iron Chelation
19
The Genetics of α -Thalassemia
20
α -Thalassemia Blood Film
21
Hb H Inclusion Bodies
22
α - Thalassemia : Hydrops Fetalis Deletion of All Four α - Globin Genes
23
Clinical Classification of Thalassemia •Hydrops fetalis
Four gene deletion of α -thalassemia
•Thalassemia major
Transfusion-dependent homozygous β -thalassemia or other
combinations
•Thalassemia intermedia Moderate severity caused by variety of genetic defects •Thalassemia minor
-thalassemia trait α -thalassemia trait β
24
Diagnosis of Thalassemia Type α -Thalassemia
Heterozygotes
Homozygotes
MCV,* MCH** low MCV, MCH low, moderate anemia, HbH
β 0-Thalassemia
MCV, MCH low, HbA2>3.5%
Thalassemia major (No HbA)
β +-Thalassemia
MCV, MCH low, HbA2>3.5%
Thalassemia intermedia (10-20% HbA)
*MCV<78 fl **MCH<26 pg
25
Treatment of Thalassemia • Thalassemia minor needs no treatment or follow up except for genetic counseling and monitoring during pregnancy. Iron deficiency should be excluded • Thalassemia major patients need life long blood transfusions, iron chelation, hormone replacement, osteoporosis prevention. Curative treatment: stem cell transplantation 26
Comparison of Currently Available Iron Chelators
Property Usual dose (mg/kg/d) Route Half-life Excretion Status
Desferrioxamine
Deferiprone
Deferasirox
25-60
75
20-30
SC, IV (8-12 hr, 5 d/wk)
Oral (3 times daily)
Oral (Once daily)
20-30 min
3-4 hr
12-16 hr
Urinary, faecal
Urinary
Faecal
Licensed
Licensed outside Approved in US, US/Canada Switzerland, and (approved in 46 30 countries countries)
Effects of Iron Chelators on Ferritin Desferrioxamine, deferiprone, and deferasirox all decrease ferritin
Mean Change in Serum Ferritin (µg/L)
Deferasirox shown to maintain and reduce serum ferritin levels in phase 2/3 clinical trials in adult and paediatric patients (12-month efficacy—serum ferritin) 2500
β-thalassaemia
SCD
β-thalassaemia, MDS, other rare anaemias
2000 1500 1000 500 0 -500 -1000 -1500
Deferasirox
5
10 Doses (mg/kg/day)
MDS: myelodysplastic syndrome; SCD: sickle cell disease.
20
30
Hemoglobinopathies
29
Molecular Pathology of Sickle Cell Anemia
30
The Oxygenated and Deoxygenated Hemoglobin Molecule
31
Pathophysiology of Sickle Cell Disease
32
Polymerization of Deoxygenated Sickle Hemoglobin in Various Tissues and Depolymerization of Reoxygenated Hemoglobin in the Lungs
33
Induction of Red-Cell Sickling by Polymerization of Deoxyhemoglobin S
34
Principal Interactions Responsible for the Adhesion of a Sickle Red Cell to the Microvascular Endothelium
35
The Process of Vaso-Occlusion in Patients with Sickle Cell Disease
Hebbel, R. P. N Engl J Med 2000;342:1910-1912
36
Clinical Features of Sickle Cell Anemia
The clinical expression is very variable Severe hemolytic anemia Painful vaso-occlusive crises Visceral sequestration crises Aplastic crises Hemolytic crises Infections are a major problem: S. pneumoniae, H. influenzae, Salmonella Lower leg ulcers, proliferative retinopathy, gallstones 37
Peripheral Blood of Sickle Cell Anemia
38
Scanning EM of a Sickle Cell
39
Sickle cell
Normal erythrocyte
40
Leg Ulcer in Sickle Cell Anemia
41
Toes in Sickle Cell Anemia
42
Pulmonary Infiltrates in Sickle Cell Anemia
43
Treatment of Sickle Cell Anemia General health care maintenance: immunizations, prophylactic penicillin, folic acid, adequate hydration Prompt treatment of infections (particularly children with high fever) Transfusion therapy to maintain Hb~10g/dl Adequate pain control: analgesics, inhaled NO Hydroxyurea Bone marrow transplantation 45
Mechanisms of Action of Hydroxyurea in Sickle Cell Disease
46
47
Mechanism of the Beneficial Effects of Hydroxyurea Therapy
48
תלסמיה בישראל
• ביתא תלסמיה נפוצה בין יהודים ממוצא מזרחי וערבים • נשאים ניתנים לגילוי ע"י ספירת דם ע"י אינדקסים של הכדוריות אדומות ואלקטרופורזיס של המוגלובין )(↑Hb A2
• יעוץ גנטי נדרש באם האם נשאית • אלפא תלסמיה פחות שכיחה מביתא תלסמיה .נפוצה באותן עדות. • נשאים מאובחנים ע"י שלילת מצבים אחרים הגורמים לשינויים באינדקסים של הכדוריות אדומות אך אבחנה מלאה דורשת בדיקת ד.נ.א 49
אנמיה חרמשית בישראל
•
• • • •
•
אנמיה חרמשית לא קיימת ביהודים .נפוצה רק בין ערבים בדואים שמוצאם מאפריקה וכן בין עובדים זרים ממוצא אפריקני. שכיחה בעיקר בגליל בישובים עם אוכלוסיה בדואית בצפון הארץ קיימת תכנית גילוי נשאים הכוללת ספירת דם )גילוי נשאי תלסמיה( ו ) HPLCגילוי (HbS, HbC, HbD באם האם מתגלה כנשאית נבדק האב ובהמשך נעשה אבחון טרום לידתי תכנית הגלוי הורידה את מספר לידות החולים 50